Associated inflammation or increased flow-mediated shear stress, but not pressure alone, disrupts endothelial caveolin-1 in infants with pulmonary hypertension

Pulmonary Circulation

Volumn 2, Issue 4, 2012, Pages 492-500

  Dereddy, Narendra ^a   Huang, Jing ^a   Erb, Markus ^a   Guzel, Sibel ^a   Wolk, John H ^a   Sett, Suvro S ^a   Gewitz, Michael H ^a   Mathew, Rajamma ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Congenital heart defect; Endothelial cells; Lung disease; Smooth muscle cells

Indexed keywords

EID: 84891498401     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.4103/2045-8932.105038     Document Type: Article

References (43)

1. Mathew R, Gewitz MH. Pulmonary hypertension in infancy and childhood. Heart Dis 2000;2:362-8.
2. Rudolph AM. Congenital cardiovascular malformations and the fetal circulation. Arch Dis Child Fetal Neonatal Ed 2010;95:F132-6.
3. Ghorishi Z, Milstein JM, Poulain FR, Moon-Grady A, Tacy T, Bennett SH, et al. Shear stress paradigm for perinatal fractal arterial network remodeling in lambs with pulmonary hypertension and increased pulmonary blood flow. Am J Physiol Heart Circ Physiol 2007;292:H3006-18.
4. Jakkula M, Le Cras TD, Gebb S, Hirth KP, Tuder RM, Voelkel NF, et al. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol 2000;279:L600-7.
5. Farquhar M, Fitzgerald DA. Pulmonary hypertension in chronic neonatal lung disease. Pediatr Respir Rev 2010;11:149-53.
6. Celermajer DS, Cullen S, Deanfield JE. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation 1993;87:440-6.
7. Mathew R, Zeballos GA, Tun H, Gewitz MH. Role of nitric oxide and endothelin 1 in monocrotaline-induced pulmonary hypertension in rats. Cardiovasc Res 1995;30:739-46.
8. Adnot S, Raffestin B, Eddahibi S, Braquet P, Chabrier P. Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest 1991;87:155-62.
9. Sbaa E, Frérart F, Feron O. The double regulation of endothelial nitric oxide synthase by caveolae and caveolin: A paradox solved through the study of angiogenesis. Trends Cardiovasc Med 2005;15:157-62.
10. Mathew R. Cell-specific dual role of caveolin-1 in pulmonary hypertension. Pulm Med 2011;2011:573432
11. Liu P, Rudick M, Anderson RG. Multiple functions of caveolin-1. J Biol Chem 2002;277:41295-8.
12. Pike LJ. Lipid ratfts: Bringing order to chaos. J Lipid Res 2003;44:655-67.
13. 2+-dependent signal transduction. Traffic 2003;4:717-23.
14. Quest AF, Leyton L, Párraga M. Caveolins, caveolae and lipid rafts in cellular transport, signaling and diseases. Biochem Cell Biol 2004;82:129-44.
15. Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev 2004;84:1341-79.
16. Jasmin JF, Mercier I, Sotgia F, Lisanti MP. SOCS proteins and caveolin-1 as negative regulators of endocrine signaling. Trends Endocrin Metab 2006;17:150-8.
17. Mathew R. Inflammation and pulmonary hypertension. Cardiol Rev 2010;18:67-72.
18. Mathew R, Huang J, Shah M, Patel K, Gewitz M, Sehgal PB. Disruption of endothelial cells caveolin-1/raft scaffolding during the development of monocrotaline-induced pulmonary hypertension. Circulation 2004;110:499-506.
19. Mathew R, Huang J, Gewitz MH. Pulmonary artery hypertension: Caveolin-1 and eNOS Interrelationship: A new perspective. Cardiol Rev 2007;15:143-9.
20. Huang J, Kaminski P, Edwards J, Yeh A, Wolin MS, Frishman WH, et al. Pyrrolidine Dithiocarbamate Restores Endothelial Cell Membrane Integrity and Attenuates Monocrotaline-induced Pulmonary Artery Hypertension. Am J Physiol Lung Cell mol Physiol 2008;294:L1250-9.
21. Mathew R, Huang J, Katta US, Krishnan U, Sandoval C, Gewitz MH. Immunosuppressant- induced endothelial damage and pulmonary arterial hypertension. J Pediatr Hematol Oncol 2011;33:55-8.
22. Patel HH, Zhang S, Murray F, Suda RY, Head BP, Yokoyama U, et al. Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension. FASEB J 2007;21:2970-9.
23. Jordan MB, Filipovich AH. Hematopoitic cell transplantation for hemophagocytic lymphohistiocytosis: A journey of a thousand miles begins with a single (big) step. Bone Marrow Transplant 2008;42:433-7.
24. Frank PG, Woodman SE, Park DS, Lisanti MP. Caveolin, caveolae and endothelial function. Arterioscle Thromb Vasc Biol 2003;23:1161-8.
25. Huang J, Wolk JH, Gewitz MH, Mathew R. Caveolin-1 expression during the progression of pulmonary hypertension. Exp Biol Med 2012;237:956-65.
26. Jasmin JF, Mercier I, Hnasko R, Cheung MW, Tanowitz HB, Dupuis R, et al. Lung remodeling in pulmonary hypertension after myocardial infarction: Pathogenic role of reduced caveolin expression. Cardiovasc Res 2004;63:747-55.
27. Achcar RO, Demura Y, Rai PR, Taraseviciene-Stewart L, Kasper M, Voelkel NF, et al. Loss of caveolin-1 and heme oxygenase expression in severe pulmonary hypertension. Chest 2006;129:696-705.
28. Huang J, Wolk JH, Gewitz MH, Mathew R. Progressive endothelial cell damage in an inflammatory model of pulmonary hypertension. Expt Lung Res 2010;36:57-66.
29. Ewenstein BM, Warhol MJ, Handin RI, Pober JS. Composition of the von Willebrand factor storage organelle (Weibel Palade body) isolated from cultured human umbilical vein endothelial cells. J Cell Biol 1987;104:1423-33
30. Lip GY, Blann A. von Willebrand factor: A marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997;34:255-65.
31. Collados MT, Sandoval J, Lopez S, Masso FA, Páez A, Borbolla JR, et al. Characterization of von Willebrand factor in primary pulmonary hypertension. Heart Vessels 1999;14:246-52.
32. Kawut SM, Horn EM, Berekashvili KK, Widlitz AC, Rosenzweig EB, Barst RJ. Von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension. Chest 2005;128:2355-62.
33. Kümpers P, Nickel N, Lukasz A, Golpon H, Westerkamp V, Olsson KM, et al. Circulating angiopoietins in idiopathic pulmonary arterial hypertension. Eur Heart J 2010;31:2291-300.
34. Smadja DM, Gaussem P, Mauge L, Israël-Biet D, Dignat-George F, Peyrard S, et al. Circulating endothelial cells: A new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation 2009;119:374-81.
35. Hardin CD, Vallejo J. Caveolins in vascular smooth muscle cells: Form organizing function. Cardiovasc Res 2006;69:808-15.
36. Hassan GS, Williams TM, Frank PG, Lisanti MP. Caveolin-1-deficient aortic smooth muscle cells show cell autonomous abnormalities in proliferation, migration, and endothelin-based signal transduction. Am J Physiol 2006;290:H2393-401.
37. Li C, Xu Q. Mechanical stress-initiated signal transductions in vascular smooth muscle cells. Cell Signalling 2000;12:435-45.
38. Sedding DG, Braun-Dullaeus RC. Caveolin-1: Dual role for proliferation of vascular smooth muscle cells. Trends Cardiovasc Med 2006;16:50-5.
39. Kawabe J, Okumura S, Lee MC, Sadoshima J, Ishikawa Y. Translocation of caveolin regulates stretch-induced ERK activity in vascular smooth muscle cells. Am J Physiol 2004;286:H1845-52.
40. Mnjoyan ZH, Doan D, Brandon JL, Felix K, Sitter CL, Rege AA, et al. The critical role of the intrinsic VSMC proliferation and death programs in injury-induced neointimal hyperplasia Am J Physiol 2008;294: H2276-84.
41. Ramirez MI, Pollack L, Millien G, Cao YX, Hinds A, Williams MC. The alpha-isoform of caveolin-1 is a marker of vasculogenesis in early lung development. J Histochem Cytochem 2002;50:33-42.
42. Grover TR, Parker TA, Balasubramaniam V, Markham NE, Abman SH. Pulmonary hypertension impairs alveolarization and reduces lung growth in ovine fetus. Am J Physiol Lung Cell Mol Physiol 2005;288:L648-54.
43. Murata T, Kinoshita K, Hori M, Kuwahara M, Tsubone H, Karaki H, et al. Statin protects endothelial nitric oxide synthase activity in hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol 2005;25: 2335-42.